Alcohol use disorder (AUD) is a major global public health issue, affecting more than 28 million adults in the United States ...

There is initial evidence that low-dose semaglutide may reduce craving and drinking outcomes in individuals with alcohol-use disorder.

There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

Teens who have parental permission to drink are more likely to develop unhealthy relationships with alcohol as adults, a ...

A JAMA Network Open study published March 13 found that 90% of Medicaid managed care plans cover at least one alcohol use ...

For years, people taking GLP-1 type drugs (e.g., Ozempic, Wegovy) have noticed that the medicines didn’t just help them to ...

While more research is needed, experts consider semaglutide a promising development in addressing alcohol addiction.

The company unveiled plans last week to test its GLP-1/glucagon dual receptor agonist in alcohol use disorder and ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

(HealthDay News) — Low-dose semaglutide seems to reduce craving and certain drinking outcomes in alcohol use disorder (AUD), according to a study published online Feb. 12 in JAMA Psychiatry. Christian ...

Semaglutide shows promise in reducing alcohol cravings and consumption. Could it be a future treatment for AUD?

Veronica Jimenez, program director for the Webb County Community Coalition of SCAN, talks about National Drug and Alcohol ...